Prestige Consumer Healthcare (Prestige Consumer Healthcare) Interest Expense

: $-71 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Prestige Consumer Healthcare's interest expense for the three months ended in Dec. 2023 was $ -17 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-71 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Prestige Consumer Healthcare's Operating Income for the three months ended in Dec. 2023 was $ 87 Mil. Prestige Consumer Healthcare's Interest Expense for the three months ended in Dec. 2023 was $ -17 Mil. Prestige Consumer Healthcare's Interest Coverage for the quarter that ended in Dec. 2023 was 5.24. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Prestige Consumer Healthcare Interest Expense Historical Data

The historical data trend for Prestige Consumer Healthcare's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => -105.08 [6] => -96.22 [7] => -82.33 [8] => -64.29 [9] => -69.16 )

Prestige Consumer Healthcare Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Interest Expense

-105.08

-96.22

-82.33

-64.29

-69.16

Prestige Consumer Healthcare Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense																-17.92	-18.98	-17.72	-17.61	-16.58

Prestige Consumer Healthcare Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-71 Mil.

Prestige Consumer Healthcare (NYSE:PBH) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Prestige Consumer Healthcare's Interest Expense for the three months ended in Dec. 2023 was $-17 Mil. Its Operating Income for the three months ended in Dec. 2023 was $87 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $1,206 Mil.

Prestige Consumer Healthcare's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	86.832	/	-16.575
	=	5.24

The higher the ratio, the stronger the company's financial strength is.

Prestige Consumer Healthcare (Prestige Consumer Healthcare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prestige Consumer Healthcare Inc (NYSE:PBH) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

PBV:Germany

Address

660 White Plains Road, Tarrytown, NY, USA, 10591

Website

https://www.prestigebrands.com

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Executives

Mary Beth Fritz	officer: Senior VP Quality & Regulatory	660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Ronald M. Lombardi	officer: Chief Executive Officer	660 WHITE PLAINS RD., TARRYTOWN NY 10591
James Darecca	director	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Christine Sacco	officer: Chief Financial Officer	C/O SMART BALANCE, INC., 115 WEST CENTURY ROAD, SUITE 260, PARAMUS NJ 07652
Adel Mekhail	other: EVP, Marketing & Sales	660 WHITE PLAINS RD., 2ND FL, TARRYTOWN NY 10591
William P'pool	officer: See Remarks	2400 WEST LLOYD EXPRESSWAY, EVANSVILLE IL 47721
Celeste A. Clark	director	C/O ADVANCEPIERRE FOODS HOLDINGS, INC., 9987 CARVER ROAD, BLUE ASH OH 45242
Christopher J Coughlin	director
Natale S Ricciardi	director	C/O MORRIS COMMUNICATIONS CORP, 725 BROAD ST., AUGUSTA GA 30903
James M Jenness	director	PO BOX 3599, BATTLECREEK MI 49016-3599
John E Byom	director	660 WHITE PLAINS RD., TARRYTOWN NY 10591
Sheila Hopkins	director	C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016
Dawn M. Zier	director	600 OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Jeffrey Zerillo	officer: Senior VP Operations	660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Timothy Connors	officer: Chief Marketing Officer	660 WHITE PLAINS RD., SUITE 205, TARRYTOWN NY 10591